** Shares of Rhythm Biosciences RHY.AX rise as much as 33.3% to A$0.20, their highest level since August 6, 2025
** The medical diagnostics tech firm secures a multi-year commercial supply agreement executed with U.S.-based Quansys Biosciences for ColoSTAT reagent kit manufacturing
** Agreement provides scalable manufacturing capacity to support ColoSTAT Access Program and commercial rollout, adds co
** About 1.5 million shares change hands, 2.3x the 30-day average
** YTD, stock up 37% year, including the day's move
(Reporting by Sherin Sunny in Bengaluru)
((Sherin.Sunny@thomsonreuters.com))